PHARMACEUTICAL DEVELOPMENT
ICH HARMONISED TRIPARTITE GUIDELINE

TABLE OF CONTENTS

PART I: 7
PHARMACEUTICAL DEVELOPMENT 7
1. INTRODUCTION 7
1.1 Objective of the Guideline 7
1.2 Scope 8
2. PHARMACEUTICAL DEVELOPMENT 8
2.1 Components of the Drug Product 11
2.1.1 Drug Substance 11
2.1.2 Excipients 12
2.2 Drug Product 13
2.2.1 Formulation Development 13
2.2.2 Overages 15
2.2.3 Physicochemical and Biological Properties 15
2.3 Manufacturing Process Development 16
2.4 Container Closure System 18
2.5 Microbiological Attributes 19
2.6 Compatibility 20
3. GLOSSARY 21
PART II: 22
PHARMACEUTICAL DEVELOPMENT - ANNEX 22
1. INTRODUCTION 23

2. ELEMENTS OF PHARMACEUTICAL DEVELOPMENT 26
2.1 Quality Target Product Profile 26
2.2 Critical Quality Attributes 26
2.3 Risk Assessment: Linking Material Attributes and Process Parameters to Drug Product CQAs 28
2.4 Design Space 29
2.4.1 Selection of Variables 29
2.4.2 Describing a Design Space in a Submission 29
2.4.3 Unit Operation Design Space(s) 30
2.4.4 Relationship of Design Space to Scale and Equipment 31
2.4.5 Design Space Versus Proven Acceptable Ranges 31
2.4.6 Design Space and Edge of Failure 32
2.5 Control Strategy 32
2.6 Product Lifecycle Management and Continual Improvement 35
3. SUBMISSION OF PHARMACEUTICAL DEVELOPMENT AND RELATED INFORMATION IN COMMON TECHNICAL DOCUMENTS (CTD) FORMAT 35
3.1 Quality Risk Management and Product and Process Development 36
3.2 Design Space 36
3.3 Control Strategy 37
3.4 Drug Substance Related Information 37
4. GLOSSARY 38
Appendix 1. Differing Approaches to Pharmaceutical Development 40
Appendix 2. Illustrative Examples 42